GILD — Gilead Sciences
Health Care|Biotechnology
3 Articles
GILDEarningspositive
Gilead Sciences Reports $6.78 EPS for 2025, Beating Street Estimates
Gilead Sciences delivered strong Q4 2025 results with full-year EPS of $6.78 and net income of $8.51 billion, demonstrating robust operational performance.
3 min read
GILDM&Apositive
Gilead to Acquire Arcellx for $115 Per Share Plus CVR in $5.2B Deal
Gilead Sciences agrees to buy CAR-T cell therapy developer Arcellx for $115 per share plus contingent value rights, valuing the transaction at up to $5.2 billion.
3 min read
GILDInsider Buyneutral
Gilead Sciences Reports $2M Share Transaction in Unusual SEC Filing
Gilead Sciences disclosed a 3.7 million share transaction valued at $2 million, with shares priced at $0.53 in an atypical insider filing.
2 min read